Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Growth in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 40,400 shares, a growth of 260.7% from the March 31st total of 11,200 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 55,500 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st.

Context Therapeutics Trading Up 2.2 %

NASDAQ:CNTX traded up $0.03 during mid-day trading on Friday, hitting $1.41. 19,984 shares of the company’s stock traded hands, compared to its average volume of 51,268. The company has a fifty day moving average of $1.25 and a 200 day moving average of $1.13. Context Therapeutics has a twelve month low of $0.47 and a twelve month high of $1.69.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.07). On average, research analysts predict that Context Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Context Therapeutics stock. Affinity Asset Advisors LLC grew its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 22.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 328,817 shares of the company’s stock after purchasing an additional 61,243 shares during the period. Affinity Asset Advisors LLC owned approximately 2.06% of Context Therapeutics worth $497,000 at the end of the most recent quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.